Compare Fabrinet (FN) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Smith & Nephew plc — how do they compare? Fabrinet trades at $501.6 (market cap $17.46B), while Smith & Nephew plc trades at $27.22 (market cap $11.10B). The key difference: Fabrinet is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Fabrinet pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and Smith & Nephew plc for 120 Days on average.
| FN | SNN | |
|---|---|---|
Market Cap | $17.46B | $11.10B |
Volume | 1,199,886 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $746.47 | $37.17 |
52-Week Low | $361.94 | $26.42 |
Typical Hold Time | 30 Days | 120 Days |
Enterprise Value | $16.59B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $497.99, up 1.81% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 45% year-over-year revenue growth in Q4 2026 and consistent earnings beats, driven by surging AI data center demand. Valuation ratios like P/E of 37.34 and P/S of 3.81 reflect high growth expectations. Recent news highlights capacity expansion and AI-driven growth, though high RSI levels suggest potential overbought conditions.
The outlook for FN is positive, with a consensus price target of $769.50 implying significant upside. Key opportunities include AI infrastructure demand and operational leverage, but risks involve customer concentration, margin pressure from high spending, and insider selling. Investors should weigh strong growth prospects against valuation and execution risks in a competitive sector.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
